Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

Mark Farrah Associates (MFA), www.markfarrah.com, reviewed data on Elevance Health, Inc.'s (NYSE:ELV) Anthem Blue Cross and Blue Shield subsidiary's acquisition of Indiana University Health Plans (IU Health Plans) on December 31, 2024. Data was obtained utilizing multiple products available to MFA's customers, including the NEW Enrollment Analysis tables in Medicare Benefits AnalyzerTM and the improved mapping capabilities under its County Health CoverageTM product's new user interface. Understanding why Elevance Health, Inc., the second largest health insurer in the United States, acquired IU Health Plans, a small, local, provider-owned insurance carrier, helps to gain insights into futu

Elevance Health (NYSE:ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-405-7292 – No Access Code (Domestic Replay) 203-369-0604 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 23, 2025, until the end of the day on Februar

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+" (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN). In addition, AM Best has affi

Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. You may also access the link here. For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation. To listen to the live webcast, please visit Elevance Health's website www.elevancehealth.com at least 15 minutes early to downloa

Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

3Q 2024 operating revenue of $44.7 billion 3Q 2024 adjusted operating gain1 of $2.4 billion 3Q 2024 diluted EPS2 of $4.36; adjusted diluted EPS1 of $8.37 4Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger." Gail K. Boudre

Elevance Health (NYSE:ELV) will release third quarter 2024 financial results on October 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-510-4837 – No Access Code (Domestic Replay) 203-369-1943 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 17, 2024, until the end of the day on November 16, 2024. The call

Argus upgraded Elevance Health from Hold to Buy and set a new price target of $450.00

Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously

Argus downgraded Elevance Health from Buy to Hold

BofA Securities downgraded Elevance Health from Buy to Neutral and set a new price target of $530.00 from $646.00 previously

Morgan Stanley initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $643.00

Robert W. Baird initiated coverage of Elevance Health with a rating of Outperform and set a new price target of $649.00

Barclays initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $584.00

Wolfe Research downgraded Elevance Health from Outperform to Peer Perform

Morgan Stanley upgraded Elevance Health from Equal-Weight to Overweight and set a new price target of $571.00 from $500.00 previously

Cantor Fitzgerald initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $547.00

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

4 - Elevance Health, Inc. (0001156039) (Issuer)

DEFA14A - Elevance Health, Inc. (0001156039) (Filer)

DEFA14A - Elevance Health, Inc. (0001156039) (Filer)

DEF 14A - Elevance Health, Inc. (0001156039) (Filer)

8-K - Elevance Health, Inc. (0001156039) (Filer)

10-K - Elevance Health, Inc. (0001156039) (Filer)

8-K - Elevance Health, Inc. (0001156039) (Filer)

8-K - Elevance Health, Inc. (0001156039) (Filer)

424B3 - Elevance Health, Inc. (0001156039) (Filer)

FWP - Elevance Health, Inc. (0001156039) (Subject)

424B3 - Elevance Health, Inc. (0001156039) (Filer)

Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV). Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with m

Mark Kaye named Executive Vice President, Chief Financial Officer Elevance Health (NYSE:ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company's executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition. Gallina's distinguished career

Duo Health, a new type of medical group purpose-built to care for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in value-based collaborations with local providers, announced the appointment of Raul Smith as Chief Financial Officer. Smith brings nearly two decades of financial leadership and growth-stage executive experience to the role, where he will lead Duo Health's strategic financial operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230803074729/en/(Photo: Business Wire) Prior to joining Duo Health, Smith served in senior roles at Elevance Health Inc. (NYSE:ELV) including President o

PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today. The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized tr

Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

Elevance Health (NYSE:ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-405-7292 – No Access Code (Domestic Replay) 203-369-0604 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 23, 2025, until the end of the day on Februar

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+" (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN). In addition, AM Best has affi

3Q 2024 operating revenue of $44.7 billion 3Q 2024 adjusted operating gain1 of $2.4 billion 3Q 2024 diluted EPS2 of $4.36; adjusted diluted EPS1 of $8.37 4Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger." Gail K. Boudre

Elevance Health (NYSE:ELV) will release third quarter 2024 financial results on October 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-510-4837 – No Access Code (Domestic Replay) 203-369-1943 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 17, 2024, until the end of the day on November 16, 2024. The call

2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which

Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-391-9851 – No Access Code (Domestic Replay) 203-369-3268 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call w

1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement Elevance Health, Inc. (NYSE:ELV) reported first quarter 2024 results. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results fo

Collaboration will leverage the strengths of three care provider entities that will come together to deliver value to consumers and employers across the healthcare journey Elevance Health, Inc. (NYSE:ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience, and improve health outcomes. This effort, which will operate across multiple regions of the United States, will bring together certain care delivery and enablement assets of Elevance Health's Carelon Health and CD&R portfolio companies, apree health and Millennium Physician Group (MPG). "CD&R's collaboration wit

SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

SC 13G - Elevance Health, Inc. (0001156039) (Subject)

SC 13G - Elevance Health, Inc. (0001156039) (Subject)

SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)